Radnostix, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 44 full-time employees. The firm manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The firm provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The firm manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The firm also manufactures Cobalt-60 sealed source products.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
Revenue
13
2
3
3
3
3
Revenue Growth (YoY)
0%
-33%
0%
0%
50%
0%
Cost of Revenue
5
1
1
1
1
1
Gross Profit
7
1
1
2
2
2
Selling, General & Admin
8
2
1
2
1
1
Research & Development
0
0
0
0
0
0
Operating Expenses
8
2
2
2
2
2
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
0
0
0
0
0
0
Income Tax Expense
--
--
--
--
--
--
Net Income
0
0
0
0
0
0
Net Income Growth
--
--
--
--
--
--
Shares Outstanding (Diluted)
527.47
527.47
528.08
527.35
524.08
523.07
Shares Change (YoY)
1%
1%
1%
1%
1%
1%
EPS (Diluted)
0
0
0
0
0
0
EPS Growth
--
-260%
-233%
-40%
-33%
-350%
Free Cash Flow
0
0
0
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
53.84%
50%
33.33%
66.66%
66.66%
66.66%
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are RADNOSTIX, INC.'s key financial statements?
According to the latest financial statement (Form-10K), RADNOSTIX, INC. has a total asset of $0, Net loss of $0
What are the key financial ratios for INIS?
RADNOSTIX, INC.'s Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is RADNOSTIX, INC.'s revenue broken down by segment or geography?
RADNOSTIX, INC. largest revenue segment is Theranostics, at a revenue of 6,841,094 in the most earnings release.For geography, United States is the primary market for RADNOSTIX, INC., at a revenue of 13,070,336.
Is RADNOSTIX, INC. profitable?
no, according to the latest financial statements, RADNOSTIX, INC. has a net loss of $0
Does RADNOSTIX, INC. have any liabilities?
no, RADNOSTIX, INC. has liability of 0
How many outstanding shares for RADNOSTIX, INC.?
RADNOSTIX, INC. has a total outstanding shares of 0